Eli Lilly’s ongoing technology evaluation agreement with Peptron, signed in October 2024 and extended through October 7, 2026, remains strictly limited to joint research on applying the SmartDepot microsphere platform to Lilly’s peptide candidates, including certain GLP-1 agents. This non-exclusive, non-binding stage grants only internal R&D rights, permits termination on 30 days’ notice, and explicitly excludes commercial licensing or technology transfer. With the deadline now days away and no public announcement of a definitive commercial deal despite nearly two years of in-vivo studies and expanded CNS research, traders assign an 87.5% implied probability to “No.” Lilly has instead advanced alternative long-acting delivery partnerships, such as its work with Camurus, while Peptron continues independent development of PT403 and manufacturing capacity. The short remaining window and absence of binding commitments reinforce the current market consensus.
Polymarket ডেটা রেফারেন্স করে পরীক্ষামূলক AI-জেনারেটেড সারাংশ। এটি ট্রেডিং পরামর্শ নয় এবং এই মার্কেট কীভাবে রেজলভ হয় তাতে কোনো ভূমিকা রাখে না। · আপডেটেডEli Lilly licenses Peptron’s SmartDepot by October 7?
Eli Lilly licenses Peptron’s SmartDepot by October 7?
13% সম্ভাবনা
$11,414 Vol.
$11,414 Vol.
Oct 7, 2026
13% সম্ভাবনা
$11,414 Vol.
$11,414 Vol.
Oct 7, 2026
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s ongoing technology evaluation agreement with Peptron, signed in October 2024 and extended through October 7, 2026, remains strictly limited to joint research on applying the SmartDepot microsphere platform to Lilly’s peptide candidates, including certain GLP-1 agents. This non-exclusive, non-binding stage grants only internal R&D rights, permits termination on 30 days’ notice, and explicitly excludes commercial licensing or technology transfer. With the deadline now days away and no public announcement of a definitive commercial deal despite nearly two years of in-vivo studies and expanded CNS research, traders assign an 87.5% implied probability to “No.” Lilly has instead advanced alternative long-acting delivery partnerships, such as its work with Camurus, while Peptron continues independent development of PT403 and manufacturing capacity. The short remaining window and absence of binding commitments reinforce the current market consensus.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
মার্কেট ওপেন হয়েছে: May 5, 2026, 8:02 PM ET
ভলিউম
$11,414শেষ তারিখ
Oct 7, 2026মার্কেট ওপেন হয়েছে
May 5, 2026, 8:02 PM ETরেজলভার
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s ongoing technology evaluation agreement with Peptron, signed in October 2024 and extended through October 7, 2026, remains strictly limited to joint research on applying the SmartDepot microsphere platform to Lilly’s peptide candidates, including certain GLP-1 agents. This non-exclusive, non-binding stage grants only internal R&D rights, permits termination on 30 days’ notice, and explicitly excludes commercial licensing or technology transfer. With the deadline now days away and no public announcement of a definitive commercial deal despite nearly two years of in-vivo studies and expanded CNS research, traders assign an 87.5% implied probability to “No.” Lilly has instead advanced alternative long-acting delivery partnerships, such as its work with Camurus, while Peptron continues independent development of PT403 and manufacturing capacity. The short remaining window and absence of binding commitments reinforce the current market consensus.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
ভলিউম
$11,414শেষ তারিখ
Oct 7, 2026মার্কেট ওপেন হয়েছে
May 5, 2026, 8:02 PM ETরেজলভার
0x65070BE91...Eli Lilly’s ongoing technology evaluation agreement with Peptron, signed in October 2024 and extended through October 7, 2026, remains strictly limited to joint research on applying the SmartDepot microsphere platform to Lilly’s peptide candidates, including certain GLP-1 agents. This non-exclusive, non-binding stage grants only internal R&D rights, permits termination on 30 days’ notice, and explicitly excludes commercial licensing or technology transfer. With the deadline now days away and no public announcement of a definitive commercial deal despite nearly two years of in-vivo studies and expanded CNS research, traders assign an 87.5% implied probability to “No.” Lilly has instead advanced alternative long-acting delivery partnerships, such as its work with Camurus, while Peptron continues independent development of PT403 and manufacturing capacity. The short remaining window and absence of binding commitments reinforce the current market consensus.
Polymarket ডেটা রেফারেন্স করে পরীক্ষামূলক AI-জেনারেটেড সারাংশ। এটি ট্রেডিং পরামর্শ নয় এবং এই মার্কেট কীভাবে রেজলভ হয় তাতে কোনো ভূমিকা রাখে না। · আপডেটেড
বাহ্যিক লিংক থেকে সাবধান।
বাহ্যিক লিংক থেকে সাবধান।
সচরাচর জিজ্ঞাসা